{"DataElement":{"publicId":"3265500","version":"2","preferredName":"AIDS-Related Kaposi Sarcoma Immunosuppression Extent Stage","preferredDefinition":"Term to describe the disease stage for an individual with AIDS-related Kaposi's sarcoma, using the AIDS Clinical Trials group staging classification to evaluate the degree of immunosuppression present.","longName":"AIDSKS_IMMUN_EXT_STG","context":"CCR","contextVersion":"1","DataElementConcept":{"publicId":"3265494","version":"1","preferredName":"AIDS-Related Kaposi Sarcoma Immunosuppression Extent","preferredDefinition":"The most aggressive form of Kaposi sarcoma.  It presents in patients who are infected with the human immunodeficiency virus.  It can affect the skin and internal organs._An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response._The range, magnitude, or distance over which a thing spans an interval of distance, space, or time.","longName":"AIDSKS_IMMUN_EXT","context":"CCR","contextVersion":"1","ObjectClass":{"publicId":"3265489","version":"1","preferredName":"AIDS-Related Kaposi Sarcoma","preferredDefinition":"The most aggressive form of Kaposi sarcoma.  It presents in patients who are infected with the human immunodeficiency virus.  It can affect the skin and internal organs.","longName":"C3992","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS-Related Kaposi Sarcoma","conceptCode":"C3992","definition":"The most aggressive form of Kaposi sarcoma. It presents in patients who are infected with the human immunodeficiency virus. It can affect the skin and internal organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABBDB1FF-1311-6351-E040-BB89AD4318BE","latestVersionIndicator":"Yes","beginDate":"2011-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-08-30","modifiedBy":"ONEDATA","dateModified":"2011-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"3265492","version":"1","preferredName":"Immunosuppressive Effect Extent","preferredDefinition":"An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response.:The range, magnitude, or distance over which a thing spans an interval of distance, space, or time.","longName":"C40913:C25332","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Immunosuppressive Effect","conceptCode":"C40913","definition":"An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Extent","conceptCode":"C25332","definition":"The range, magnitude, or distance over which a thing spans an interval of distance, space, or time.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABBDB1FF-135B-6351-E040-BB89AD4318BE","latestVersionIndicator":"Yes","beginDate":"2011-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-08-30","modifiedBy":"ONEDATA","dateModified":"2011-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABBDB1FF-136C-6351-E040-BB89AD4318BE","latestVersionIndicator":"Yes","beginDate":"2011-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-08-30","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3265496","version":"2","preferredName":"AIDS-Related Kaposi Sarcoma Immunosuppression Stage","preferredDefinition":"The most aggressive form of Kaposi sarcoma.  It presents in patients who are infected with the human immunodeficiency virus.  It can affect the skin and internal organs_An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response._The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"AIDSKS_IMMUN_STG","context":"CCR","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"42","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"I1 - CD4 cells < 200 per cubic millimeter","valueDescription":"I1 - CD4 cells < 200 per cubic millimeter ","ValueMeaning":{"publicId":"3430903","version":"1","preferredName":"I1 - CD4 cells < 200 per cubic millimeter ","longName":"3430903","preferredDefinition":"A laboratory test result which indicates decreased levels of CD4 lymphocytes in a biospecimen.: A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.: A number with no fractional part, including the negative and positive numbers as well as zero.::200: A metric unit of volume equal to one millionth of a liter or one one thousandth of a milliliter.: A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin however, it may also occur internally.  It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"CD4 Lymphocytes Decreased","conceptCode":"C78233","definition":"A laboratory test result which indicates decreased levels of CD4 lymphocytes in a biospecimen.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"4"},{"longName":"Less Than","conceptCode":"C61585","definition":"A statement about the relative size or order of two objects specifying that an object of interest is smaller than another object in quantity or measure or value or status.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Integer","conceptCode":"C45255","definition":"A number with no fractional part, including the negative and positive numbers as well as zero.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Microliter","conceptCode":"C48153","definition":"A unit of volume accepted for use with the SI and equal to one millionth of a liter (10E-6 liter).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Kaposi Sarcoma","conceptCode":"C9087","definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BCB3BEE9-912D-FD16-E040-BB89AD434541","latestVersionIndicator":"Yes","beginDate":"2012-04-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BCB3BEE9-9146-FD16-E040-BB89AD434541","beginDate":"2011-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-02","modifiedBy":"ONEDATA","dateModified":"2012-04-02","deletedIndicator":"No"},{"value":"I0 - Good Risk","valueDescription":"I0 - Good Risk","ValueMeaning":{"publicId":"3430902","version":"1","preferredName":"I0 - Good Risk","longName":"3430902","preferredDefinition":"Valuable or useful or agreeable or pleasing.\r\n: Risk is the potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable. (from WIkipedia): An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response.: A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin however, it may also occur internally.  It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Good","conceptCode":"C64975","definition":"Valuable or useful or agreeable or pleasing.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"3"},{"longName":"Risk","conceptCode":"C17102","definition":"The potential future harm that may arise from some present action. It is often combined or confused with the probability of an event which is seen as undesirable.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Immunosuppressive Effect","conceptCode":"C40913","definition":"An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Kaposi Sarcoma","conceptCode":"C9087","definition":"A malignant neoplasm characterized by a vascular proliferation which usually contains blunt endothelial cells. Erythrocyte extravasation and hemosiderin deposition are frequently present. The most frequent site of involvement is the skin; however it may also occur internally. It generally develops in people with compromised immune systems including those with acquired immune deficiency syndrome (AIDS).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BCB3BEE9-9104-FD16-E040-BB89AD434541","latestVersionIndicator":"Yes","beginDate":"2012-04-02","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-02","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"BCB3BEE9-911D-FD16-E040-BB89AD434541","beginDate":"2011-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-02","modifiedBy":"ONEDATA","dateModified":"2012-04-02","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008549","version":"1","preferredName":"Involvement and Extent of Disease","preferredDefinition":"indication of the presence and extent of disease.","longName":"INV_AND_EXT_OF_DZ","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B22AA815-A017-5261-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-19","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-19","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3265495","version":"1","preferredName":"AIDS-Related Kaposi Sarcoma Immunosuppressive Effect Stage","preferredDefinition":"The most aggressive form of Kaposi sarcoma.  It presents in patients who are infected with the human immunodeficiency virus.  It can affect the skin and internal organs.:An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response.:The extent of a cancer within the body, especially whether the disease has spread from the original site to other parts of the body.","longName":"C3992:C40913:C16899","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"AIDS-Related Kaposi Sarcoma","conceptCode":"C3992","definition":"The most aggressive form of Kaposi sarcoma. It presents in patients who are infected with the human immunodeficiency virus. It can affect the skin and internal organs.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Immunosuppressive Effect","conceptCode":"C40913","definition":"An Immunosuppressive Effect involves interference with, or restraint of, the function of biologic molecules and complexes, or cellular, cell, or tissue components of a normal immune response.","evsSource":"CTCAE_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Neoplasm Stage","conceptCode":"C16899","definition":"The extent of a cancer in the body.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"ABBDB1FF-1384-6351-E040-BB89AD4318BE","latestVersionIndicator":"Yes","beginDate":"2011-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2011-08-30","modifiedBy":"ONEDATA","dateModified":"2011-08-30","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"BCB3BEE9-90B6-FD16-E040-BB89AD434541","latestVersionIndicator":"Yes","beginDate":"2011-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-02","modifiedBy":"REEVESD","dateModified":"2012-04-02","changeDescription":"v2.0 extends max length from 2 to 42 characters","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008601","version":"1","longName":"C3D Domain","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811685","version":"1","longName":"CCR","context":"CCR"}]},{"publicId":"2182125","version":"1","longName":"CCR Implementation","context":"CCR","ClassificationSchemeItems":[{"publicId":"2811673","version":"1","longName":"C3D","context":"CCR"}]}],"AlternateNames":[],"ReferenceDocuments":[{"name":"I (Immune system)","type":"Preferred Question Text","description":"I (Immune system)","url":null,"context":"CCR"}],"origin":"ACTG TIS Classification:AIDS Clinical Trials Group staging classification for AIDS-associated Kaposi's sarcoma","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"BCB5619C-8EB1-3686-E040-BB89AD43356C","latestVersionIndicator":"Yes","beginDate":"2011-08-30","endDate":null,"createdBy":"REEVESD","dateCreated":"2012-04-02","modifiedBy":"REEVESD","dateModified":"2015-05-19","changeDescription":"Curated for NCI CCR trial; v2.0 replaces v1.0 with reworked Value domain and permissible value set","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}